Who Paid My Doc
Himala Kashmiri
Pediatric Endocrinology Orange, CA Doctor of Osteopathy
NPI 1386808285 CMS profile 659071
1201 W La Veta Ave, Orange, CA 92868
General payments
$5,206
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$107,541
Through program year 2025, Himala Kashmiri of Orange, CA is reported in the CMS Open Payments database as having received $5,206 across 179 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $107,541 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 75th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,129 | 36 | |
| 2024 | General | $797 | 26 | |
| 2023 | General | $1,075 | 32 | |
| 2022 | General | $955 | 22 | |
| 2021 | General | $438 | 19 | |
| 2020 | General | $128 | 7 | |
| 2019 | General | $684 | 37 |
Beside peers
- Himala Kashmiri
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Himala Kashmiri were reported at $1,129. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Himala Kashmiri | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $684 | $196 | $68–$845 | $163 |
| 2020 | $128 | $124 | $37–$722 | $114 |
| 2021 | $438 | $134 | $35–$691 | $132 |
| 2022 | $955 | $177 | $47–$726 | $149 |
| 2023 | $1,075 | $236 | $75–$887 | $160 |
| 2024 | $797 | $259 | $91–$979 | $164 |
| 2025 | $1,129 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
179 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in California
Gnanagurdasan Prakasam
Pediatric Endocrinology · Sacramento, CA
Swati Elchuri
Pediatric Endocrinology · Ventura, CA
Karen Klein
Pediatric Endocrinology · San Diego, CA
Francine Kaufman
Pediatric Endocrinology · Los Angeles, CA
Lynda Polgreen
Pediatric Endocrinology · Orange, CA
Kevin Kaiserman
Pediatric Endocrinology · West Covina, CA
Related records
Pediatric Endocrinology in California
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.